ABBV enters Q1 earnings with Skyrizi and Rinvoq as the focal growth drivers while legacy Humira sales continue to decline. Investors will be watching uptake in new indications and market-share gains to determine whether those products can offset Humira erosion and support near-term revenue and guidance.
ABBV enters Q1 earnings with Skyrizi and Rinvoq as the focal growth drivers while legacy Humira sales continue to decline. Investors will be watching uptake in new indications and market-share gains to determine whether those products can offset Humira erosion and support near-term revenue and guidance.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
